← Leaderboards
Amanda Jayne Law
University Of Colorado Denver
$3,629,630
Attributed
$3,629,630
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $511.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,629,630 · 2
By mechanism
R01$3,629,630 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Freedman$18,290,612
- Randal G Ross$11,799,906
- Linda F Van Dyk$7,612,861
- Karen E Stevens$1,195,425
- Sharon K Hunter$912,173
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelPathway InteractionsGeneticMolecularNeurodevelopmentNeuronsElectrophysiology (Science)GenesLinkMemoryNeurobiological MechanismArhgef5 GeneCognitive FunctionNeurodevelopmental DisorderBrainCognition DisordersBehaviorBehavioralCellsCognitionBiologicalMediatingNeuregulin 1Phenotype
Grant awards (8)
Neuregulin/Alpha7nAChR Signaling, the GABAergic Switch and Neurodevelopmental Risk: Mechanisms of Gestational Choline Supplementation.$494,695
R01 · FY2025 · HD · contact PI
Neuregulin/Alpha7nAChR Signaling, the GABAergic Switch and Neurodevelopmental Risk: Mechanisms of Gestational Choline Supplementation.$489,748
R01 · FY2024 · HD · contact PI
Neuregulin/Alpha7nAChR Signaling, the GABAergic Switch and Neurodevelopmental Risk: Mechanisms of Gestational Choline Supplementation.$511,554
R01 · FY2023 · HD · contact PI
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.$419,850
R01 · FY2018 · MH · contact PI
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.$419,850
R01 · FY2017 · MH · contact PI
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.$419,850
R01 · FY2016 · MH · contact PI
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.$419,850
R01 · FY2015 · MH · contact PI
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.$454,233
R01 · FY2014 · MH · contact PI